Disclaimer: This article is for research and educational purposes only. BPC-157 and TB-500 are research compounds that are not approved by the FDA, Health Canada, or any regulatory body for human therapeutic use. Nothing in this article constitutes medical advice. These compounds are intended strictly for licensed research applications.
Few peptide combinations have attracted as much community attention as the pairing of BPC-157 and TB-500 — commonly referred to online as the “Wolverine Stack.” Named after the Marvel character known for rapid healing, the combination has become shorthand in research and fitness communities for a dual-peptide protocol theorized to address tissue repair across multiple systems.
In 2026, search interest around “BPC-157 TB-500 stack” and “Wolverine stack” continues to grow — but most of the content ranking for these terms skips straight to dosing protocols and vendor recommendations without pausing to examine what the evidence actually supports, what the risks look like, or where both compounds stand legally.
This post provides a rigorous, honest review of all three dimensions.
What Are BPC-157 and TB-500?
BPC-157 (Body Protection Compound-157)
BPC-157 is a synthetic pentadecapeptide consisting of 15 amino acids. It was originally derived from a protective protein isolated from human gastric juice. The compound has been studied primarily in rodent models since the 1990s and has never completed a human clinical trial.
Its proposed mechanisms — still largely preclinical — include:
- Angiogenesis stimulation (new blood vessel formation)
- Upregulation of growth hormone receptors in tendon fibroblasts
- Modulation of nitric oxide (NO) pathways
- Gut mucosal protective effects
TB-500 (Thymosin Beta-4 Fragment)
TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4) — a naturally occurring 43-amino acid protein found throughout the body, including in platelets, wound fluid, and most tissues. TB-500 typically refers to the Tβ4 fragment comprising amino acids 17–23 (the actin-binding domain), though vendors use the term inconsistently.
This is a critical distinction: TB-500 is not the same as thymosin beta-4. Some vendors treat the terms interchangeably, but the fragment and the full protein have different structural properties and, potentially, different research profiles.
Thymosin beta-4’s proposed research roles include:
- Actin sequestration and cytoskeletal regulation
- Wound healing and tissue remodeling
- Anti-inflammatory signaling
- Cardiac and nerve tissue protection (in animal models)
What Does the Evidence Actually Show?
BPC-157 — Evidence by Tissue Type
| Tissue / System | Evidence Level | Notes |
|—|—|—|
| Tendon / Ligament | Moderate (animal) | Multiple rodent models show accelerated Achilles and other tendon healing |
| Gastrointestinal | Moderate (animal) | Ulcer healing and mucosal protection; strongest preclinical evidence base |
| Skeletal Muscle | Low–Moderate (animal) | Crush and laceration models in rats |
| Nerve / CNS | Low (animal) | Peripheral nerve and some CNS models; small study counts |
| Bone | Low (animal) | Limited fracture-healing observations |
| Cardiovascular | Very low (animal) | Preliminary data only |
| Human clinical trials | None | No completed Phase 1, 2, or 3 trials published as of May 2026 |
TB-500 (Thymosin Beta-4 Fragment) — Evidence by Tissue Type
| Tissue / System | Evidence Level | Notes |
|—|—|—|
| Wound healing / skin | Moderate (animal + early human) | Thymosin beta-4 (full protein) has been studied in a small number of human wound trials; results are modest |
| Cardiac tissue | Low–Moderate (animal) | Tβ4 has shown cardioprotective effects in ischemia models in rodents |
| Corneal healing | Low–Moderate (animal) | Some preclinical evidence; corneal trials ongoing for full Tβ4 protein |
| Skeletal muscle | Low (animal) | Limb ischemia and muscle regeneration models |
| Tendon | Low (animal) | Less studied than BPC-157 in tendon models |
| Human clinical trials | Very limited | Small trials have studied full thymosin beta-4 protein, not the TB-500 fragment specifically |
Important note: The majority of human clinical research involves full thymosin beta-4 protein, not the TB-500 fragment. The assumption that TB-500’s effects mirror those of the full protein is not validated in human trials.
What the “Stack” Claims vs. What the Evidence Supports
The appeal of the Wolverine Stack is mechanistic complementarity: BPC-157 is theorized to work through growth hormone receptor upregulation and angiogenesis, while TB-500 targets actin dynamics and anti-inflammatory pathways. In theory, these mechanisms are non-overlapping and potentially additive.
Here’s an honest claim-vs-evidence table:
| Common Claim | Evidence Level | Reality |
|—|—|—|
| “Stacking provides faster tendon healing” | Speculative | No combined-compound studies published in any species |
| “BPC-157 + TB-500 have synergistic effects” | Theoretical | Based on mechanistic extrapolation, not trial data |
| “The stack works for ligament injuries” | Preclinical only | BPC-157 has some rodent data; TB-500 ligament data is minimal |
| “The Wolverine Stack is used by elite athletes” | Anecdotal | No published sports medicine research on the combination |
| “The stack is safe for humans” | Unknown | No human safety data for either compound in combination |
The core problem: no published research examines BPC-157 and TB-500 in combination in any species. All “stack” claims are theoretical extrapolations from separate single-compound animal studies. This doesn’t mean the research interest is unfounded — it means the stack framework runs well ahead of the evidence.
Regulatory Status in 2026: Both the U.S. and Canada
United States
BPC-157: The FDA’s updated 503A bulk substances list (May 14, 2026) no longer includes BPC-157 in Category 2. However, this does not grant it compounding approval — it simply means it’s not under active Category 2 review. BPC-157 is not FDA-approved and has no NDA. It occupies regulatory ambiguity: not prohibited under Category 3, but not permitted for compounding either.
TB-500: TB-500 (as the Tβ4 fragment) is similarly not on the FDA’s 503A approval list and is not FDA-approved for any indication. The full thymosin beta-4 protein has been investigated by pharmaceutical companies but has not received FDA approval for any condition.
For U.S. researchers: both compounds are research-use-only. Any retail or compounding sale for human use exists in a legally grey zone that increased FDA scrutiny in 2026 is likely to tighten further.
Canada
Neither BPC-157 nor TB-500 hold a Drug Identification Number (DIN) or Natural Product Number (NPN) from Health Canada. Both are available as research reagents through licensed suppliers for laboratory research applications.
Canadian researchers sourcing these compounds should ensure:
- Complete Certificate of Analysis (CoA) with HPLC purity data
- Mass spectrometry sequence confirmation
- Third-party testing documentation
- Purchase from a licensed Canadian research reagent supplier
A Note on TB-500 vs. Thymosin Beta-4: The Vendor Confusion Problem
A persistent problem in the TB-500 space is that many vendor and community sites use “TB-500” and “thymosin beta-4” interchangeably. They are not the same compound.
- Thymosin beta-4 (Tβ4) is a full 43-amino acid protein with known structural and functional characteristics.
- TB-500 is specifically a synthetic peptide fragment of Tβ4 — the 17–23 residue segment that contains the actin-binding LKKTETQ sequence.
The distinction matters for research because:
1. The fragment’s bioavailability and in vivo activity may differ significantly from the full protein.
2. Human clinical research on full Tβ4 cannot be directly applied to TB-500 fragment findings.
3. Purity specifications and synthesis standards for the fragment need to be evaluated independently.
When reading competitor content, vendor sites, or even some academic summaries, watch for this conflation — it’s widespread and can lead to incorrect conclusions about the evidence base.
Frequently Asked Questions
Q: Is the Wolverine Stack legal to research in Canada?
BPC-157 and TB-500 can be sourced separately as research reagents in Canada for licensed laboratory research applications. Neither compound has a Health Canada DIN or NPN. They are not approved for human therapeutic use. Researchers should verify applicable regulatory requirements for their institution.
Q: Has any research actually studied BPC-157 and TB-500 together?
As of May 2026, no published peer-reviewed research has studied BPC-157 and TB-500 in combination in any species. All “stack” rationales are based on theoretical complementarity between each compound’s proposed individual mechanisms.
Q: Is TB-500 the same as thymosin beta-4?
No. TB-500 is a synthetic fragment (residues 17–23) of the full thymosin beta-4 protein. The compounds have related but distinct structural properties. Human clinical research on thymosin beta-4 cannot be directly applied to TB-500.
Q: What are the primary risks associated with these compounds in research contexts?
Because neither compound has completed human clinical trials, the full human safety profile is unknown. In animal studies, BPC-157 and TB-500 have generally shown benign profiles at studied doses, but GI adverse events have been noted with BPC-157 in some models. The absence of human safety data means all risk characterization for human exposure remains speculative.
Q: What’s the best evidence available for BPC-157 specifically?
BPC-157’s strongest preclinical evidence base is in gastrointestinal and tendon/ligament models in rodents. Multiple independent research groups have replicated gastric mucosal protection effects. Tendon healing data is also relatively consistent across studies. These are the areas where the research is most developed — though the absence of human trials means all findings remain preclinical.
Conclusion
The BPC-157 + TB-500 Wolverine Stack has earned its search volume — the mechanistic logic is interesting and the individual compounds have a meaningful preclinical evidence base. But the “stack” itself is a theoretical construct with no combined-compound research behind it, and both compounds remain research-only with no regulatory approval in the U.S. or Canada.
For researchers approaching this space seriously, the right framework is: evaluate each compound’s evidence base independently, apply appropriate research-only framing to all work, source from suppliers with rigorous third-party documentation, and treat all human-outcome extrapolations from animal data with appropriate caution.
WebberScience supplies research-grade BPC-157 and TB-500 with full HPLC purity data, mass spectrometry confirmation, and Certificate of Analysis documentation for Canadian research institutions. For sourcing details, specifications, or questions about your research program, contact our team or browse our research catalog.
This article is for educational and informational purposes only. BPC-157 and TB-500 are research compounds not approved for human use by the FDA, Health Canada, or any regulatory body. This content does not constitute medical advice.